Long-Term Follow-Up of Patient with Diabetic Macular Edema Receiving Fluocinolone Acetonide Intravitreal Implant.

Abstract

IntroductionThis case study aims to evaluate outcomes following fluocinolone acetonide [FAc 0.2 μg/day; ILUVIEN® (Alimera Sciences Limited, Aldershot, UK)] implant in a patient with diabetic macular edema (DME) not responding to laser photocoagulation or anti-vascular endothelial growth factor (anti-VEGF) therapy and to compare FAc implant with anti-VEGF therapy in the fellow eye.Case ReportThe author presents here a patient with DME for around 20 years in both eyes, who had undergone pan-retinal and focal photocoagulation, and anti-VEGF therapy in both eyes without resolution of DME. FAc implant in the left, and subsequently in the right eye, provided substantial improvements in edema and visual acuity.ConclusionIn the current case, a benefit was demonstrated in the FAc implant-treated left eye at a time when the right eye was not responding to anti-VEGF injections. If a patient does not respond well to an anti-VEGF (i.e. first-line therapy) in one eye, the treating physician should consider switching the patient to a corticosteroid implant (such as FAc implant) in the fellow eye.Electronic supplementary materialThe online version of this article (doi:10.1007/s40123-015-0028-0) contains supplementary material, which is available to authorized users.